NCT06678230 2024-11-07
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
Phase 2 Unknown
Clinical Trials
11 trialsNCT06340165 2024-04-01
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
The First Hospital of Jilin University
Unknown
NCT04914390 2024-01-22
NeoATCT
Sichuan Provincial People's Hospital
Phase 2 Unknown
NCT06015126 2023-08-29
Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients
Xi'an International Medical Center Hospital
Phase NA Unknown
NCT05558722 2022-09-28
ACNTBC
Xijing Hospital
Phase 2 Unknown
NCT05089643 2022-01-10
Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04975451 2021-07-27
ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Guangdong Women and Children Hospital
Phase 2 Unknown
NCT04452370 2021-07-21
Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04936295 2021-06-23
Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation
Sun Yat-sen University
Phase 2 Unknown
NCT04764084 2021-02-21
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
Peking University Cancer Hospital & Institute
Phase 1 Unknown
NCT04405505 2020-05-28
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown